 SALT LAKE CITY, March 03, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries, Clene today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences: 